---
title: "CITIC International expects that the release of the value of 707 drugs will drive 3SBIO upward"
description: "The research report from China Merchants Bank International indicates that the drug development program 707/PF'4404, a collaboration between Pfizer and 3SBIO, has progressed beyond expectations, with "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274079636.md"
published_at: "2026-01-29T02:30:04.000Z"
---

# CITIC International expects that the release of the value of 707 drugs will drive 3SBIO upward

> The research report from China Merchants Bank International indicates that the drug development program 707/PF'4404, a collaboration between Pfizer and 3SBIO, has progressed beyond expectations, with four global Phase 3 clinical studies expected to start in 2026. This drug is anticipated to become a cornerstone of the next generation of tumor immunotherapy, driving up 3SBIO's stock price. Based on increased competition, the target price has slightly decreased to 37.43 yuan, maintaining a "Buy" rating

Zhaoyin International's research report indicates that Pfizer (PFE.US) recently disclosed a significant R&D plan for 707/PF’4404 (PD-1/VEGF) in collaboration with 3SBIO (01530.HK), with progress exceeding the bank's expectations in both speed and scope. Pfizer has clearly stated that it will initiate four global Phase 3 clinical trials in 2026, covering five major first-line indications, and will also launch Phase 3 clinical studies in combination with ADC drugs for the first time.

The bank believes that the PD-(L) 1/VEGF dual antibody is expected to become a cornerstone drug for the next generation of tumor immunotherapy, and Pfizer is likely to gain a competitive advantage in the race due to the synergistic advantages of its "IO+ADC" internal pipeline and strong clinical execution capabilities. The global value release of 707/PF’4404 will also become a key catalyst for driving 3SBIO's upward momentum.

Based on intensified competition, the bank has adjusted the Beta and perpetual growth rate, slightly lowering the target price for 3SBIO from HKD 37.58 to HKD 37.43, while maintaining a "Buy" rating

### Related Stocks

- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 津巴布韋推出新型 HIV 預防藥物 lenacapavir | 津巴布韋推出了長效 HIV 預防藥物 lenacapavir，目標是覆蓋超過 46,000 名高風險個體，分佈在 24 個地點。該項目由美國和全球基金資助，分階段進行，衞生部長道格拉斯·蒙貝肖拉強調了其在抗擊 HIV 中的重要性。lenac | [Link](https://longbridge.com/en/news/276333424.md) |
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |
| 阿伯丁集團有限公司持有 Crinetics Pharmaceuticals, Inc. $CRNX 價值 1416 萬美元的股票 | 阿伯丁集團 plc 在第三季度將其在 Crinetics Pharmaceuticals, Inc. 的股份增加了 21.3%，目前持有 339,949 股，價值 1416 萬美元。其他機構投資者也調整了他們的持股。分析師對 CRNX 的評 | [Link](https://longbridge.com/en/news/276426109.md) |
| 這位輝瑞分析師以看空的基調開始覆蓋；以下是週五的五大新啓動 | 華爾街頂級分析師已對多家公司啓動了覆蓋。Baird 的 David Koning 對 Affirm Holdings (AFRM) 給予中性評級，目標價為 55 美元。Piper Sandler 的 Biren Amin 對 OKYO Ph | [Link](https://longbridge.com/en/news/276467088.md) |
| Eupraxia 籌集了 5500 萬美元以加速 EP-104GI 及其 GI 研發管線 | Eupraxia Pharmaceuticals 宣佈公開發行約 5500 萬美元的普通股和預先融資的認股權證，預計於 2026 年 2 月 20 日完成交易。資金將用於推進其 EP-104GI 候選藥物，並擴大對胃腸疾病的研究。Eupra | [Link](https://longbridge.com/en/news/276313525.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.